We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Arecor Therapeutics Plc | AREC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 76.50 | 08:00:09 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 76.50 | 76.50 | 78.00 | 76.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 24/9/2024 07:44 by jonesy100 There is an AREC results presentation being hosted by LSE on Thursday. Maybe we will find out then whether there is something badly wrong. |
Posted at 04/12/2023 13:16 by 127tolmers As foreshadowed in the TD report which calculated potential values of such a deal:Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces a co-development and exclusive licence option agreement with a leading global medical products company for a high-value, ready-to-dilute (“RTD”) oncology product from Arecor’s in-house Specialty Hospital pipeline. Under the terms of the agreement, Arecor and its partner will conduct further co-development and regulatory work with Arecor eligible to receive potential developmental milestones. The agreement includes an option for the partner to be granted an exclusive, worldwide license to further develop and commercialise the product, with Arecor eligible to receive milestones and royalty payments. Arecor has developed a proprietary RTD form of a lyophilized powder product using its formulation technology platform, Arestat™. This novel, liquid, RTD formulation of an existing ‘blockbuster&# |
Posted at 01/12/2023 17:28 by gleach23 That's some trade for AREC reported late today - 60,735 @ 191.54p |
Posted at 28/6/2023 07:04 by alloa2003 As the AREC treatments are effectively improvements on existing treatments you would assume there would be little concern about toxicity etc in the trials. I would therefore be surprised if the initial feedback from the treatment is not confirmed via the trials? |
Posted at 21/3/2023 16:55 by sharesoc In case you missed our webinar with Arecor Therapeutics plc (AREC) earlier this month, the recording can be found on our YouTube channel: |
Posted at 24/2/2023 22:01 by sharesoc ShareSoc is hosting a webinar with Arecor Therapeutics plc (AREC) on 07 March 2023, which may be of interest to current shareholders or potential investors. Sarah Howell Ph.D (Chief Executive Officer) and Susan Lowther (Chief Financial Officer) will be presenting. You can register here: |
Posted at 02/8/2022 11:11 by timbo003 see new Trinity Delta research note on AREC (issued yesterday) |
Posted at 31/3/2022 22:39 by sharesoc In case you missed our webinar with Arecor Therapeutics (AREC), the recording can be found on our YouTube channel: |
Posted at 23/3/2022 07:38 by alloa2003 Nice progress:-ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS Further strengthens the Company's extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio Cambridge, UK, 23 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11278624) protecting novel formulations of the Group's proprietary insulin products, AT247 and AT278. Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "Arecor's novel insulin products, based on a combination of existing insulin analogues and our highly innovative formulation science, have potential to improve convenience, compliance and enable more effective management of blood glucose for people living with type 1 and type 2 diabetes. As the clinical validation of the superiority of these products compared to current gold standard prandial insulins continues, we are also advancing the intellectual property protection for these products. This recently granted US patent, the first within the Group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress." Arecor has invested in building a strong patent portfolio to protect the Arestat™ technology platform and its proprietary pipeline products. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >50 granted patents in Europe, the US and in other key territories. As part of this strategy, Arecor has robust IP directed to the novel insulin compositions that protect different aspects of AT247 and AT278 formulations, as well as their specific properties and methods of use. Arecor's strategy is to generate a fortress of both narrow and broad interrelated IP rights that cover the features of these products. US11278624 is the first granted US patent within the Group's comprehensive insulin IP strategy. |
Posted at 20/1/2022 07:46 by alloa2003 "Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has commenced the USPhase I clinical trial of Arecor's lead product, AT247, an ultra-rapid insulin to be delivered by continuous subcutaneous infusion via insulin pump over a period of three days." Should hopefully get the company and its treatment line back in the news again. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
